Health and Consultancy Services in Cuba
CIMAvax-EGF: Detailed Information and User Guide
What is CIMAvax-EGF? CIMAvax-EGF is an innovative cancer vaccine developed in Cuba. Produced by the Center for Molecular Immunology, this vaccine is specifically designed for patients with advanced non-small cell lung cancer (NSCLC). CIMAvax-EGF activates the immune system by targeting epidermal growth factor (EGF), which triggers the growth of cancer cells, and inhibits the growth of tumor cells by neutralizing this factor.
Structure and Ingredients of CIMAvax-EGF This vaccine is created by chemically combining Epidermal Growth Factor (EGF) with P64k, a protein. It is also administered with Montanide ISA 51 VG adjuvant to stimulate the immune system. The vaccine is administered in four injections, with each injection delivering this chemical compound to the patient. Each dose is administered by intramuscular injection at different injection sites (gluteal and deltoid)
Mechanism of Action of CIMAvax-EGF Cancer cells use a protein called epidermal growth factor (EGF) to receive signals to grow and multiply. CIMAvax-EGF neutralizes this protein by causing the body to produce antibodies against EGF. As a result of this neutralization, EGF is prevented from binding to its receptors on the cell, leading to a halt in cell proliferation and suppression of tumor growth
Areas of Vaccine Use CIMAvax-EGF is used after the first chemotherapy treatment, especially in patients with advanced non-small cell lung cancer (NSCLC). Clinical trials have shown prolonged survival and improved quality of life in patients receiving the vaccine. The vaccine was more effective in patients with high serum levels of EGF. The vaccine is preferred as a treatment to reduce metastasis and slow disease progression in these patients
Clinical Outcomes and Efficacy CIMAvax-EGF'nin etkinliği üzerine yapılan klinik çalışmalar, aşının özellikle EGF seviyeleri yüksek hastalarda önemli sonuçlar verdiğini göstermektedir. Çalışmalar, CIMAvax-EGF ile tedavi edilen hastaların hayatta kalma oranlarının, aşı uygulanmayan kontrol gruplarına kıyasla anlamlı derecede daha uzun olduğunu göstermiştir. Örneğin, bir klinik araştırmada, aşı uygulanan hastaların ortalama yaşam süresi 12,43 ay olurken, kontrol grubunda bu süre 9,43 ay olarak kaydedilmiştir. Bu, hastalar için %23 oranında daha düşük ölüm riski anlamına gelir
Serum EGF seviyeleri yüksek olan hastalarda (EGF ≥ 870 pg/mL) bu oran daha da yüksek olup, bu hastalar için ölüm riski %59 oranında azalmıştır. Bu grup hastalarda medyan yaşam süresi 14,66 aya kadar çıkmıştır. Bu sonuçlar, EGF seviyelerinin yüksek olmasının aşı tedavisinde önemli bir biyomarker (belirteç) olduğunu göstermektedir
Treatment Process and Method of Application The treatment consists of two stages:
- Induction Phase: This phase starts with patients receiving a single dose of cyclophosphamide (200 mg/m²). Three days later, CIMAvax-EGF injections are started. The first four doses are given every two weeks.
- Maintenance Phase: After the induction phase, maintenance vaccinations are administered monthly. This maintenance treatment continues as long as the patient's general health permits.
Each dose is administered by injection into four different sites (both gluteal and deltoid regions). Each injection consists of some antigen and adjuvant
Side Effects and Safety CIMAvax-EGF is generally well tolerated and does not cause serious side effects. Clinical studies show that side effects are mostly limited to local reactions such as mild pain at the injection site, redness and sometimes mild fever. More rarely, systemic effects such as headache, chills and shortness of breath may occur, but these effects are usually mild and transient
Who is not suitable for? The use of CIMAvax-EGF is not suitable for pregnant women, nursing mothers, children and patients with active infections. It is also not recommended for patients with heart failure, uncontrolled arrhythmias or other serious health problems
Obtaining CIMAvax-EGF Patients who wish to receive CIMAvax-EGF treatment, "Health and Counseling Services in Cuba" through which they can access this treatment. Our company offers comprehensive consulting services on the administration of this vaccine and the necessary medical examinations. Before starting treatment, a detailed medical evaluation is carried out by our specialized doctors and the most appropriate treatment plan is created for patients.
Our Services
- Medical Evaluation: Comprehensive examinations are carried out to determine whether treatment is appropriate.
- Treatment Planning: In cooperation with the best health centers in Cuba, patient-specific treatment plans are prepared.
- Continuous Monitoring During the treatment process, the condition of the patients is regularly monitored and intervened when necessary.
To learn more about CIMAvax-EGF and access this innovative treatment contact us you can move on.
Apply Online Now!
Filling Out the Application Form
Payment of Preliminary Examination and Registration Fee
